Latest News

The FDA has set a PDUFA date of December 30, 2026.

Data from the ACCESS II trial, ACCESS extension study, and a body composition study provide an early look at efficacy and safety data of a new investigational oral GLP-1.

Phase 3 FIND-CKD shows finerenone slows non-diabetic CKD decline by improving eGFR slope; Bayer prepares FDA filing for expanded use.

Lebrikizumab posts strong Phase 3 gains in infants to teens with atopic dermatitis, supporting FDA label expansion and itch relief.

An audio recap of the top 5 stories in healthcare news from the week of 03/02-03/08.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new trial data, in this week’s essential news roundup.

This FDA approval of secukinumab (Cosentyx) for hidradenitis suppurativa (HS) represents the fourth pediatric indication for the drug.

In this feature, 3 experts discuss the expansion of telehealth and telemedicine use, including their positive and negative aspects in dermatology today.

New biologics transform severe asthma and COPD, yet prednisone overuse persists—see practical selection tips and outpatient steroid stewardship gaps.

This March episode of The Medical Sisterhood, in honor of Women's History Month, covers building influence in the dermatology field as a woman physician.

Experts discuss gaps in CKD detection, the role of albuminuria testing, and the need for earlier, risk-based care to improve outcomes.

In Medical Ethics Unpacked, hosts and guest Rose Onyeali, MD, discuss how solitary confinement in prisons may accelerate physical decline and worsen cognitive health.

Experts weigh new biologics including dupilumab, tezepelumab, and depemokimab, and how eosinophils guide real-world prescribing.

Yu, MD, Adler, MD, share their perspectives from a cohort study on in-sequence, and out of sequence paired kidneys transplants.

These data, resulting from the INTEGUMENT-OLE trial, highlight the efficacy and safety of roflumilast cream (ZORYVE) 0.05% in children aged 2 - 5 years.

The approval comes after the FDA requested GSK submit an sNDA for leucovorin for the treatment of CFD-FOLR1.

This March episode highlights one SOCS member’s journey in dermatology, covering clinical and research passions as well as lessons learned along the way.

February 2026 saw new data and expert interviews from AAAAI 2026.

The FDA accepted Mineralys Therapeutics’ NDA for lorundrostat in hypertension, but the selective aldosterone synthase inhibitor fell short in a phase 2 obstructive sleep apnea trial.

Phase 3 RAINIER exhibits positive results for povetacicept in adults with IgA Nephropathy in a 36 week interim analysis.

Bimekizumab was assessed using the International Hidradenitis Suppurativa Severity Score System (IHS4) outcomes in the BE HEARD I and II studies.

New data suggest those who exhibit minimal early response to ruxolitinib cream may still achieve repigmentation with prolonged use extending to 2 years.

Stay updated with the latest healthcare breakthroughs, FDA actions, and new trial data, in this week’s essential news roundup.